Natalizumab in multiple sclerosis;Natalizumab en esclerosis múltiple

Revista de Neurologia

Volumn 49, Issue 5, 2009, Pages 265-269

  Río Izquierdo, Jordi ^a   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Effectiveness; Immunomodulators; Integrin; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

BETA INTERFERON; GLATIRAMER; MEFLOQUINE; NATALIZUMAB;

ABORTION; ALLERGIC REACTION; ANXIETY DISORDER; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HUMAN; HYPERSENSITIVITY; LEUKOENCEPHALOPATHY; LIVER DISEASE; MELANOMA; MULTIPLE SCLEROSIS; PHARYNGITIS; REVIEW; SINUS CONGESTION;

EID: 70349272983     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4905.2009447     Document Type: Review

References (37)

1. Compston A. Making progress on the natural history of multiple sclerosis. Brain 2006; 129: 561-563 (Pubitemid 43278219)
2. Menge T, Weber MS, Hemmer B, Kieseier BC, Von Büdingen HC, Warnke C, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008; 68: 2444-2468
3. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-955
4. Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997; 8: 3-16. (Pubitemid 27397156)
5. Stüve O, Bennet JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drugs Rev 2007; 13: 79-95. (Pubitemid 46697841)
6. Horga A, Horga de la Parte JF. Natalizumab en el tratamiento de la esclerosis múltiple. Rev Neurol 2007; 45: 293-303.
7. Bayless KJ, Meininger GA, Scholtz JM, Davis GE. Osteopontin is a ligand for the alpha4beta1 integrin. J Cell Sci 1998; 111 (Pt 9): 1165-1174
8. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 1994; 94: 1722-1728 (Pubitemid 2150008)
9. Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004; 4: 571-580 (Pubitemid 38890585)
10. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 1999; 52: 1072-1074 (Pubitemid 29161624)
11. Hauser SL, Weiner HL. Natalizumab: immune effects and implications for therapy. Ann Neurol 2006; 59: 731-732 (Pubitemid 43673148)
12. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libinati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23. (Pubitemid 36026342)
13. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomised, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910. (Pubitemid 43313657)
14. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1 a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923 (Pubitemid 43313658)
15. O'Connor P, Polman C, Goodman A, Kappos L, Lublin F, Rudick R, et al. Efficacy and safety of natalizumab in the STRATA study. Poster 06.127. 61st Annual Meeting of the American Academy of Neurology. Seattle, Washington, 2009.
16. Bozic C, Belcher G, Kim R, Hyde R, Lynn F, Kooijmans-Coutinho M, et al. Natalizumab in patients with relapsing multiple sclerosis: updated utilization and safety results including TOUCH and TYGRIS. Presentation 11.005. 61st Annual Meeting of the American Academy of Neurology. Seattle, Washington, 2009.
17. Biogen Idec. TYSABRI Update. URL: http://phx.corporate-ir.net/External. File?item=UGFyZW50SUQ9MTEwODd8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1. [01.07.2009].
18. Hellwig K, Schimrigk S, Fischer M, Haghikia A, Muller T, Chan A, et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008; 65: 656-658 (Pubitemid 351679662)
19. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006; 60: 162-173
20. Walker DPB. The epidemiology of human polyomaviruses. New York: Alan R. Liss; 1983.
21. Sabath, BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186 (Suppl 2): S180-6.
22. Elsner C, Dorries K. Evidence of human polyomavirus BK and JC infection in normal brain tissue. Virology 1992; 191: 72-80.
23. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lympho-proliferative disorders. Clin Infect Dis 2006; 43: 16-24. (Pubitemid 43939071)
24. Von Andrian UH, Engelhardt, B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68-72. (Pubitemid 36026351)
25. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381 (Pubitemid 41132342)
26. Gold R, Jawad A, Miller DH, Henderson DC, Fassas A, Fierz W, et al. Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 2007; 187: 156-158 (Pubitemid 47001540)
27. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005; 17: 658-665 (Pubitemid 40558222)
28. Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 2007; 64: 169-176 (Pubitemid 46256555)
29. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008; 358: 647-648 (Pubitemid 351214309)
30. Bozic C, Belcher G, Kooijmans M, Kim R, Lynn F, Panzara MA. The safety of natalizumab in patients with relapsing multiple. Update from TOUCH and TYGRIS. Poster P06.095. 59th Annual Meeting of the American Academy of Neurology. Boston, Maryland, 2007.
31. European Medicine Agency. URL: http://www.emea.europa.eu/humandocs/PDFs/ EPAR/ tysabri/H-603-en6.pdf. [30.12.2006].
32. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6: 431-441 (Pubitemid 46551850)
33. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PEH, Sellebjerg F, Sorensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Poster 06.134. 61st Annual Meeting of the American Academy of Neurology. Seattle, Washington, 2009.
34. Putzki N, Yaldizli O, St. Mäurer M, Kuckert S, Cursiefen S, Tettenborn B, et al. Natalizumab reduces clinical and MRI disease activity in second line treatment of relapsing remitting multiple sclerosis: results of a multicenter study. Poster 05.128. 61st Annual Meeting of the American Academy of Neurology. Seattle, Washington, 2009.
35. Bates D, Bartholome E, Pace A, Hyde R, Hotermans G. Effect of natalizumab on relapse outcomes in patients with relapsing MS who experience MRI activity during treatment. Poster 05.135. 61st Annual Meeting of the American Academy of Neurology. Seattle, Washington, 2009.
36. Zivadinov R, Dwyer MG, Bergsland N, Hussein S, Cox J, Durfee J, et al. Natalizumab (Tysabri) promotes remyelination in patients with multiple sclerosis. A voxel-wise magnetization transfer imaging case-control study. Poster 03.071. 61st Annual Meeting of the American Academy of Neurology. Seattle, Washington, 2009.
37. Munschauer F, Giovannoni G, Lublin F, O'Connor P, Phillips JT, Polman C. et al. Sustained improvement in physical disability with natalizumab in patients with relapsing multiple sclerosis. Poster 06.131. 61st Annual Meeting of the American Academy of Neurology. Seattle, Washington, 2009.